Cioteronel

Cioteronel

Clinical data
Routes of administration	Oral, topical
ATC code	None
Identifiers
IUPAC name 4-(5-methoxyheptyl)-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-one
CAS Number	89672-11-7
PubChem (CID)	55994
ChemSpider	50555
UNII	1RTH95874Z
ChEMBL	CHEMBL2104105
Chemical and physical data
Formula	C16H28O2
Molar mass	252.39232 g/mol
3D model (Jmol)	Interactive image
SMILES CCC(CCCCC1CCC2C1CC(=O)C2)OC
InChI InChI=InChI=1S/C16H28O2/c1-3-15(18-2)7-5-4-6-12-8-9-13-10-14(17)11-16(12)13/h12-13,15-16H,3-11H2,1-2H3 Key:KDULJHFMZBRAHO-UHFFFAOYSA-N

Cioteronel (INN, USAN) (developmental code name CPC-10997; former tentative brand names Cyoctol, Ethocyn, X-Andron) is a non-steroidal antiandrogen that was never marketed.^[1][2][3] It was under development over the course of 1989 to 2001 for the topical treatment of androgenetic alopecia (male pattern baldness) and acne and for the oral treatment of benign prostatic hyperplasia; it reached phase III clinical trials for acne and phase II studies for androgenetic alopecia, but was ultimately discontinued due to poor efficacy.^[3][4]

See also

• Delanterone
• Inocoterone
• Metogest
• Rosterolone
• Topilutamide
• Topterone
• Zanoterone

References

1. C.R. Ganellin; David J. Triggle (21 November 1996). Dictionary of Pharmacological Agents. CRC Press. pp. 570–. ISBN 978-0-412-46630-4.
2. Daniel Lednicer (21 November 1994). The Organic Chemistry of Drug Synthesis. John Wiley & Sons. pp. 11–. ISBN 978-0-471-58959-4.
3. Tiwari, Atul; Krishna, N S; Nanda, Kamna; Chugh, Anita (2005). "Benign prostatic hyperplasia: an insight into current investigational medical therapies". Expert Opinion on Investigational Drugs. 14 (11): 1359–1372. doi:10.1517/13543784.14.11.1359. ISSN 1354-3784.
4. https://adisinsight.springer.com/drugs/800003205[]